102 results
DEFA14A
AIM
AIM ImmunoTech Inc
20 Nov 23
Additional proxy soliciting materials
7:30am
’ leadership, AIM has secured government-funded clinical trials for its lead product, Ampligen. Equels 496:14-24, 500:24-501:12; JX1241; see also Equels 499 … life sciences industry organization—and has held leadership roles at major industry players like Merck, GlaxoSmithKline, and Bayer. JX0678.0002; Bryan
DEFC14A
AIM
AIM ImmunoTech Inc
6 Nov 23
Proxy in contested solicitation
9:09am
and the board leadership structure to ensure the interests of the Company and its stockholders are best served.
Currently, the independent Chairman … , Committee Chair
Dr. William M. Mitchell
Nancy K. Bryan (since March 28, 2023)
Board Role in Risk Oversight
The Board evaluates its leadership
DEFC14A
q9xd5o
1 Nov 23
Proxy in contested solicitation
5:01pm
PREC14A
pollm6bqqiwpo
13 Oct 23
Preliminary proxy with contested solicitation
4:57pm
PREC14A
e4cad6j162ibxv
10 Oct 23
Preliminary proxy with contested solicitation
9:00am
DFAN14A
qyb m3q79d4pvie
28 Aug 23
Additional proxy materials by non-management
12:52pm
8-K
EX-99.1
xluyp9
30 Mar 23
Departure of Directors or Certain Officers
8:50am
8-K
6xawiiv
30 Mar 23
Departure of Directors or Certain Officers
8:50am
DEFA14A
4i7lh5k
26 Oct 22
Additional proxy soliciting materials
5:19pm
DFAN14A
4j6ahpwkb6uzs0kew
19 Oct 22
Additional proxy materials by non-management
3:26pm
DEFC14A
ws09lik6
28 Sep 22
Proxy in contested solicitation
5:09pm
PRRN14A
6ynd76 xdd0wdo4
23 Sep 22
Revised preliminary proxy statement filed by non-management
4:59pm